{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(7)"],"submitter":["Wu SJ"],"funding":["Taiwan Ministry of Science and Technology"],"pubmed_abstract":["Carcinoembryonic antigen-related cell adhesion molecules 6 (CEACAM6) is a cell adhesion receptor. Expression of CEACAM6 in non-small cell lung cancer (NSCLC) associated with tumor progression and metastatic condition via Src/FAK signaling pathway. We established three anti-CEACAM6 antibodies with valences, which were designed to be monomeric sdAb, bivalent sdAb (2Ab), and tetravalent sdAb (4Ab). The anti-CEACAM6 antibodies can be used to target CEACAM6 overexpressing NSCLC. Anti-CEACAM6 antibodies, sdAb, 2Ab and 4Ab, were modified with different valency via protein engineering. sdAb and multivalent sdAbs (2Ab & 4Ab) were expressed and purified from E.coli and CHO cells, respectively. We compared the effect of anti-CEACAM6 antibodies with doxorubicin in NSCLC cell line both in vitro and in "],"journal":["Translational oncology"],"pagination":["101057"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8105299"],"repository":["biostudies-literature"],"pubmed_title":["Migration and invasion of NSCLC suppressed by the downregulation of Src/focal adhesion kinase using single, double and tetra domain anti- CEACAM6 antibodies."],"pmcid":["PMC8105299"],"pubmed_authors":["Wang YM","Arundhathi A","Yuan SF","Chen CY","Wu SJ","Wang HC","Cheng TM"],"additional_accession":[]},"is_claimable":false,"name":"Migration and invasion of NSCLC suppressed by the downregulation of Src/focal adhesion kinase using single, double and tetra domain anti- CEACAM6 antibodies.","description":"Carcinoembryonic antigen-related cell adhesion molecules 6 (CEACAM6) is a cell adhesion receptor. Expression of CEACAM6 in non-small cell lung cancer (NSCLC) associated with tumor progression and metastatic condition via Src/FAK signaling pathway. We established three anti-CEACAM6 antibodies with valences, which were designed to be monomeric sdAb, bivalent sdAb (2Ab), and tetravalent sdAb (4Ab). The anti-CEACAM6 antibodies can be used to target CEACAM6 overexpressing NSCLC. Anti-CEACAM6 antibodies, sdAb, 2Ab and 4Ab, were modified with different valency via protein engineering. sdAb and multivalent sdAbs (2Ab & 4Ab) were expressed and purified from E.coli and CHO cells, respectively. We compared the effect of anti-CEACAM6 antibodies with doxorubicin in NSCLC cell line both in vitro and in ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-05-29T21:42:37.894Z","creation":"2025-05-29T21:42:37.894Z"},"accession":"S-EPMC8105299","cross_references":{"pubmed":["33934053"],"doi":["10.1016/j.tranon.2021.101057"]}}